Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Systemic Sclerosis
NCT02453256Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Jan 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 22
01
Overview
A Phase 3 trial of tocilizumab in systemic sclerosis (SSc), sponsored by Roche. Started Nov 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02453256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453256.